<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412710</url>
  </required_header>
  <id_info>
    <org_study_id>FIU-032511-01</org_study_id>
    <nct_id>NCT01412710</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation on Cardiovascular Risk Factors</brief_title>
  <official_title>The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors Among Hispanics and African Americans With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida International University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present pilot study is to determine the effect of vitamin D
      supplementation (4000 IU or 6000 IU once daily for 6 months) on reducing heart disease risk
      and in improving blood glucose control in type 2 Diabetes subjects . The investigators are
      working with Hispanics and African Americans living in Miami, Florida.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insufficient vitamin D levels have been found in subjects with type 2 diabetes (T2D).
      Similarly, a negative association between serum vitamin D levels and insulin resistance has
      been reported in a large sample representative of the adult US population and in subjects at
      risk for T2D. In addition, a strong association between hypovitaminosis D and
      hypertriglyceridemia has been demonstrated in studies done in US adult population.

      Literature has indicated that subjects with T2D and insulin resistance (IR) are more likely
      to develop arteriosclerosis and all of the complications related to this condition, such as
      myocardial infarction and stroke.

      These findings have increased the interest about the effect of vitamin D on metabolic
      abnormalities grouped under the term &quot;cardiovascular disease (CVD) risk factors&quot;, which
      includes hypertension, dyslipidemia, obesity, glucose intolerance, inflammation and T2D which
      is in itself a risk factor for CVD.

      Therefore, the purpose of the present pilot study will be to determine the effect of
      supplemental vitamin D intake (4000 IU or 6000 IU of Cholecalciferol daily for 6 months) on
      CVD risk markers and glycemic control; primarily lipid panel, insulin resistance, and
      glycosylated hemoglobin (A1C), in a sample of Hispanics and African-Americans with T2D and
      vitamin D insufficiency. If repletion of vitamin D level improves insulin resistance,
      glycemic control, inflammation, hypertension, dyslipidaemia or kidney functions, it may
      prevent the development of CVD events and decrease T2D complications.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Lipid</measure>
    <time_frame>Baseline</time_frame>
    <description>Total cholesterol will be used as surrogate measures for cardiovascular disease risk.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycemic Control</measure>
    <time_frame>Baseline</time_frame>
    <description>hemoglobin A1C blood test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>4000 IU group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be given 4000 IU of vitamin D3 once daily, orally for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6000 IU group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will be given 6000 IU vitamin D3 once daily, orally for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>4000 IU or 6000 IU given vitamin D3 once daily, orally for 6 months.</description>
    <arm_group_label>4000 IU group</arm_group_label>
    <arm_group_label>6000 IU group</arm_group_label>
    <other_name>Vitamin D</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  African American or Hispanic

          -  able to ambulate on their own

          -  aged between 30 - 70 years

        Exclusion Criteria:

          -  Taking Supplemental Vitamin D

          -  Pregnant or Lactating women

          -  Receiving insulin therapy

          -  Not participating in other drug trials

          -  HIV/ hepatitis/ cancer/ liver disease/ heart failure/ any recent surgery/ mental
             illness/ epilepsy/ any GI or malabsorption disorders

          -  Kidney failure or on dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatma G Huffman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida International University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Human Nutrition Laboratory, Florida International University</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <results_first_submitted>August 5, 2017</results_first_submitted>
  <results_first_submitted_qc>November 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 12, 2017</results_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Florida International University</investigator_affiliation>
    <investigator_full_name>Fatma Ercanli-Huffman</investigator_full_name>
    <investigator_title>Dr. Fatma G. Huffman</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Cardiovascular disease risk</keyword>
  <keyword>Minorities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from two clinics in Miami-Dade County, Florida (Borinquen Health Care Center and Clinical Care Medical Center) from July 2011 to March 2013 using flyers explaining the purpose of the study.</recruitment_details>
      <pre_assignment_details>15 participants did not qualified due to normal levels of serum vitamin D, 25-hydroxy vitamin D [25(OH)D].</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>4000 IU Group</title>
          <description>This group received 4000 IU/day vitamin D3 for 6 months.</description>
        </group>
        <group group_id="P2">
          <title>6000 IU Group</title>
          <description>This group received 6000 IU/day vitamin D3 for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Hispanic or Latino and African-Americans, age 30-70 years old, with type 2 diabetes.</population>
      <group_list>
        <group group_id="B1">
          <title>4000 IU Group</title>
          <description>This group will be given cholecalciferol 4000 IU once daily, orally for 6 months.</description>
        </group>
        <group group_id="B2">
          <title>6000 IU Group</title>
          <description>This group will be given cholecalciferol 6000 IU once daily, orally for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.76" spread="8.56"/>
                    <measurement group_id="B2" value="54.17" spread="10.99"/>
                    <measurement group_id="B3" value="54.46" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Lipid</title>
        <description>Total cholesterol will be used as surrogate measures for cardiovascular disease risk.</description>
        <time_frame>Baseline</time_frame>
        <population>Total cholesterol baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>4000 IU Group</title>
            <description>Vitamin D 4000 IU/day</description>
          </group>
          <group group_id="O2">
            <title>6000 IU Group</title>
            <description>Vitamin D 6000 IU/day</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Lipid</title>
          <description>Total cholesterol will be used as surrogate measures for cardiovascular disease risk.</description>
          <population>Total cholesterol baseline.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213.08" spread="42.30"/>
                    <measurement group_id="O2" value="193.88" spread="41.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glycemic Control</title>
        <description>hemoglobin A1C blood test</description>
        <time_frame>Baseline</time_frame>
        <population>A1C baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>4000 IU Group</title>
            <description>Vitamin D 4000 IU/day</description>
          </group>
          <group group_id="O2">
            <title>6000 IU Group</title>
            <description>Vitamin D 6000 IU/day</description>
          </group>
        </group_list>
        <measure>
          <title>Glycemic Control</title>
          <description>hemoglobin A1C blood test</description>
          <population>A1C baseline.</population>
          <units>Percentage of Hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="2.40"/>
                    <measurement group_id="O2" value="8.26" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data were collected for 6 months</time_frame>
      <desc>No adverse events or signs of toxicity reported by any of the participants throughout the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>4000 IU Vitamin D3/Day</title>
          <description>This group will be given cholecalciferol 4000 IU once daily, orally for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>6000 IU Vitamin D3/Day</title>
          <description>This group will be given cholecalciferol 6000 IU once daily, orally for 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study sample was a convenience sample and was not randomly selected from the general adult population. The study lacked a control group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Fatma G. Huffman</name_or_title>
      <organization>Florida International University</organization>
      <phone>305-348-3877</phone>
      <email>huffmanf@fiu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

